title: Clearance of serum HBsAg and anti-HBs seroconversion following antiviral therapy for chronic hepatitis B.
abstract: In this study, we have analyzed the evolution of serum HBsAg levels in 16 patients with chronic hepatitis B who showed an HBsAg seroconversion following antiviral therapy. The data showed that the clearance of serum HBsAg is slower than that of serum HBV DNA, which may reflect a slow kinetics of clearance of infected hepatocytes. Interestingly, HBsAg was detectable for a longer time using the Architect assay than with the Bio-Rad assay. As viremia suppression is achieved in most patients under therapy with the new generation of nucleoside analogs, these data suggest that the quantitative monitoring of serum HBsAg may represent a novel tool for the assessment of antiviral therapy efficacy.
authors: INSERM U, Lyon, France.
authors: Olivier
authors: O
authors: Borgniet
authors: Parviz
authors: P
authors: Parvaz
authors: Cécile
authors: C
authors: Bouix
authors: Philippe
authors: P
authors: Chevallier
authors: Christian
authors: C
authors: Trépo
authors: Patrice
authors: P
authors: André
authors: Fabien
authors: F
authors: Zoulim
mesh_terms: D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D004279:DNA, Viral / Q000097:blood; D016903:Drug Monitoring / Q000379:methods; D005260:Female; D006510:Hepatitis B Antibodies / Q000097:blood*; D006514:Hepatitis B Surface Antigens / Q000097:blood*; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D006801:Humans; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens